Lin BioScience, Inc. (TPEX: 6696)
Taiwan
· Delayed Price · Currency is TWD 139.50
+5.50 (4.10%)
Dec 19, 2024, 2:59 PM CST
Lin BioScience Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2016 |
| Selling, General & Admin | 258.28 | 242.75 | 124.26 | 93.52 | 51.99 | 44.88 | Upgrade
|
| Research & Development | 1,018 | 854.07 | 320.87 | 244.76 | 145.01 | 193.35 | Upgrade
|
| Operating Expenses | 1,277 | 1,097 | 445.13 | 338.28 | 196.99 | 238.22 | Upgrade
|
| Operating Income | -1,277 | -1,097 | -445.13 | -338.28 | -196.99 | -238.22 | Upgrade
|
| Interest Expense | -1.12 | -1.2 | -0.88 | -0.07 | -0.25 | -0.35 | Upgrade
|
| Interest & Investment Income | 48.74 | 4.49 | 1.19 | 0.19 | 0.5 | 0.34 | Upgrade
|
| Currency Exchange Gain (Loss) | 4.02 | -1.95 | 8.87 | -0.53 | -0.14 | -1.79 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.3 | 4.95 | -41.93 | -151.95 | 22.09 | 0.01 | Upgrade
|
| EBT Excluding Unusual Items | -1,225 | -1,091 | -477.87 | -490.63 | -174.8 | -240.01 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | - | 0.46 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | 0.22 | - | -0.48 | Upgrade
|
| Pretax Income | -1,225 | -1,091 | -477.87 | -490.41 | -174.8 | -240.03 | Upgrade
|
| Income Tax Expense | -29.8 | -29.72 | -18.44 | -9.51 | -22.95 | -4.78 | Upgrade
|
| Earnings From Continuing Operations | -1,195 | -1,061 | -459.43 | -480.9 | -151.84 | -235.26 | Upgrade
|
| Minority Interest in Earnings | 463.29 | 373.63 | 145.91 | 46.21 | - | - | Upgrade
|
| Net Income | -731.66 | -687.19 | -313.52 | -434.7 | -151.84 | -235.26 | Upgrade
|
| Net Income to Common | -731.66 | -687.19 | -313.52 | -434.7 | -151.84 | -235.26 | Upgrade
|
| Shares Outstanding (Basic) | 77 | 74 | 72 | 69 | 62 | 60 | Upgrade
|
| Shares Outstanding (Diluted) | 77 | 74 | 72 | 69 | 62 | 60 | Upgrade
|
| Shares Change (YoY) | 6.63% | 3.14% | 4.27% | 10.73% | 4.42% | 0.03% | Upgrade
|
| EPS (Basic) | -9.49 | -9.29 | -4.37 | -6.32 | -2.44 | -3.95 | Upgrade
|
| EPS (Diluted) | -9.49 | -9.29 | -4.37 | -6.32 | -2.44 | -3.95 | Upgrade
|
| Free Cash Flow | -1,189 | -1,015 | -383.4 | -291.96 | -181.18 | -212.36 | Upgrade
|
| Free Cash Flow Per Share | -15.42 | -13.72 | -5.34 | -4.24 | -2.92 | -3.57 | Upgrade
|
| EBITDA | -1,271 | -1,091 | -442.62 | -336.79 | -195.83 | -236.62 | Upgrade
|
| D&A For EBITDA | 6.15 | 5.85 | 2.51 | 1.48 | 1.17 | 1.6 | Upgrade
|
| EBIT | -1,277 | -1,097 | -445.13 | -338.28 | -196.99 | -238.22 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.